The main purpose of this study is to determine the safety and efficacy of DII235 in adults with elevated lipoprotein(a).

Inclusion Criteria:

• Signed informed consent must be obtained prior to participation in the study.
• Male or female participants 18 to 80 years of age (inclusive) at the screening.
• Lp(a) ≥ 150 nmol/L at screening, measured at the central laboratory.
• Participants with evidence of atherosclerotic cardiovascular disease and/or type 2 diabetes mellitus.

Exclusion Criteria:

• Severe renal dysfunction
• Hepatic dysfunction
• Malignancy within the last 5 years
• Use of investigational medications as defined in the protocol
• History or presence at screening of an underlying disease, or surgical, physical, medical, or psychiatric condition that, in the opinion of the Investigator, or sponsor if consulted, would potentially affect participant safety within the study or interfere with participating in or completing the study or with the interpretation of data

Other protocol-defined inclusion/exclusion criteria may apply

Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

In order to preserve the integrity of the study and to minimize bias, a randomized double-blind study design is being used.